Fundz

Fundz Deep Dive

Everything you need to win Namsa — in one platform.

Who to reach, what to say, and why now on Namsa — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Namsa — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

NAMSA acquires WuXi AppTec's US Medical Device Testing Operations to strengthen its leadership in medical technology trials and research

PRIVATEJan 17, 2025•over 1 year ago

Acquiring Company

Namsa

Acquired Company

WuXi AppTec

ShanghaiManufacturingBiotechnologyPharmaceutical

Description

NAMSA, a leading global company in testing, clinical trials, and regulatory consulting in the medical technology field, has announced the definitive agreement to acquire WuXi AppTec's US Medical Device Testing Operations. This acquisition is aimed at expanding NAMSA's portfolio of research and clinical trial solutions, enhancing customer experience, and accelerating innovation in the medical technology field, ultimately contributing to saving lives worldwide.

Company Information

Company

Namsa

About

Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world’s only 100% medical device-focused, full continuum Contract Research Organization (CRO). Driven by its global expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move Clients’ products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, NAMSA is the industry’s premier, trusted partner for successful development and commercialization outcomes. Web: namsa.com

Related People

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Namsa's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.